89bio reports third quarter 2020 financial results and provides corporate update

– updated clinical data from bio89-100 's phase 1b/2a nash trial to be presented as a late-breaking poster at upcoming aasld liver meeting –
ETNB Ratings Summary
ETNB Quant Ranking